SHARONBIO

Sharon Bio-Medicine Limited has informed the Exchange regarding 'Intimation for consideration and declaration of Audited financial results for the year ended March 31, 2019. '.

Sharon Bio-Medicine Limited has informed the Exchange regarding 'Certificate under Regulation 74 (5) of Securities and Exchange Board of India(Depositories and Participants) Regulations 2018'.

Sharon Bio-Medicine Limited has informed the Exchange regarding 'Withdrawal of Closure Notice for the manufacturing activity of API Plant'.

Sharon Bio-Medicine Limited has informed the Exchange regarding 'Update on USFDA inspection at our API facility.'.

Sharon Bio-Medicine Limited has informed the Exchange regarding 'Recovery notice from the Commissioner of State Tax for the year 2011-12 and 2015-16'.

Sharon Bio-Medicine Limited has informed the Exchange regarding 'Closure of operations of API plant '.

Sharon Bio-Medicine Limited has informed the Exchange regarding 'Revised Letter for '.

Sharon Bio-Medicine Limited has informed the Exchange regarding 'Dismissal of petition filed by erstwhile promoters in NCLAT'.

Sharon Bio-Medicine Limited has informed the Exchange regarding 'Appointment of Mr. Kaushik Banerjee as Chief Executive Officer of the company'.

Sharon Bio-Medicine Limited has informed the Exchange regarding 'Consent to Operate for API Plant Located at L-6, MIDC,Taloja, Dist.Raigad, Maharashtra-410208'.

Sharon Bio-Medicine Limited has informed the Exchange regarding 'National Company Law Tribunal have Approved Resolution Plan submitted by Peter Beck & Partners. '.

Sharon Bio-Medicine Limited has informed the Exchange regarding 'Temporary Suspension of operations of API plant located at L-6, MIDC, Taloja, Dist. Raigad, Maharashtra �� 410208'.

Sharon Bio-Medicine Limited has informed the Exchange regarding 'Pursuant to Regulation 29(1) (a) of the SEBI (listing obligations and disclosure requirements) Regulations 2015, this is to inform you that Resolution Professional on Thursday, February 22, 2018 at 03.00 PM, will consider the Unaudited Financial Results of the Company for the Quarter ended on June 30, 2017, September 30, 2017 & December 31, 2017. '.

Sharon Bio-Medicine Limited has informed the Exchange regarding 'Submission of Resolution plan to NCLT on January 04, 2018.'.

Sharon Bio-Medicine Limited has informed the Exchange regarding 'Notice for Financial Results for the Quarter ended on March 31st, 2017.'.

Sharon Bio-Medicine Limited has informed the Exchange regarding 'Intimation for extension of CIRP Process for 90 days with effect from October 08, 2017'.

Sharon Bio-Medicine Limited has informed the Exchange regarding Financial results for the year ended March 31, 2017.

Sharon Bio-Medicine Limited has informed the Exchange the Intimation of initiation of Corporate Insolvency Resolution Process (CIRP) and appointment of Interim Resolution Professional (IRP).

Sharon Bio-Medicine Limited has informed the Exchange regarding Change of address and contact details of M/s. Link Intime India Pvt. Ltd Registrar and Share Transfer Agent of the Company.

Sharon Bio-Medicine Limited has informed the Exchange vide letter dated December 17, 2015 regarding "Intimation for clearing National Good Laboratory Practice (GLP) Compliance Monitoring Authority (NGCMA) surveillance inspection".

Sharon Bio-Medicine Limited has informed the Exchange regarding "Sharon Bio Medicine Ltd. U.S. FDA News".

Sharon Bio-Medicine Limited has informed the Exchange that M/s. India Factoring And Finance Solutions Pvt. Ltd. from whom Company have taken unsecured loan had filed the case under U/S 433 and 434 of the Companies Act, 1956. The Company has challenged the case in the Bombay High Court and asked the Honourable Court to dismiss the Petition as the same is devoid of any merit.

Sharon Bio-Medicine Limited has informed the Exchange that in the last week one of the Company's Formulation Plant at Dehradun in Uttarakhand has been Inspected and Audited by USFDA officials. This is Company's second plant which has been Inspected and Audited by USFDA officials in the last 2 months. First plant at Taloja near Navi Mumbai was Inspected and Audited in the first week of July 2015 and was intimated to the Exchange on July 9, 2015.Company hope to add Company's Active Pharma Ingredient and Formulation sales to United State Of America (USA) apart from many European and other countri

Sharon Bio-Medicine Limited has informed the Exchange that one of the Unit Located at L-6, MIDC, Taloja. Dist. Raigad, Maharashtra has been inspected and audited by USFDA inspectors for 7 days starting from June 29, 2015. The Audit was Completed on July 7, 2015. (Revised)

Sharon Bio-Medicine Limited has informed the Exchange that one of the Company unit Located at L-6, MIDC, Taloja Dist. Raigad, Maharashtra has been inspected and audited by USFDA inspectors for 7 days starting from July 06, 2015. The Audit was Completed on July 14, 2015.

Sharon Bio-Medicine Limited has informed the Exchange that the proposal for restructuring of the debts of the Company has been accepted by all its bankers, accordingly the Master Restructuring Agreement has been executed by all the bankers. The Board of Directors have already intimated regarding the restructuring of debts to the concerned stock exchanges on March 16, 2015.

Sharon Bio-Medicine Limited has informed the Exchange that the Company has received the certification for the approval of Good Manufacturing Practices (GMP) for both, Capsules and Tablets from United Kingdom - Medical & Health Care Product Regulatory Agency (UKMHRA) for its expanded area of Formulation and Tablets unit located at Selaqui, Uttarakhand. In the view of the above it should be noted that after the expansion the production capacity of the Compay's Formulation and Tablets plant located at Selaqui, Uttarakhand has been doubled in the term of production.

Sharon Bio-Medicine Limited has informed the Exchange regarding United Kingdom - Medicine & Health Care Product Regulatory Agency (UKMHRA) inspection conducted for Good Manufacturing Practices (GMP) for Company's recently Expanded Formulation Plant area located a Uttarakhand.

Sharon Bio-Medicine Limited has informed the Exchange that one of the Company's unit located at Plot No- V-10, MIDC, Taloja, near Navi Mumbai Dist. Raigad, Maharashtra has been allotted Good Laboratory Practice Certificate which is on same line as Organization for Economic Co-operation & Development Certificate (OECD). With this Sharon can do Toxicity & Mutagenicity Studies and Analytical & Clinical Chemistry Testing. This will help Sharon to help big Pharma, Chemical & Agro companies to do research in their fields. Sharon will do the studies and testing in its laboratory for the companies all

Sharon Bio-Medicine Limited has informed the Exchange that "A fire has erupted in one of our API and Intermediate Plant located at Plot no W-34 & W-34/1, MIDC, Taloja Dist. Raigad, Maharashtra. The incident took place today as on June 03, 2014. No Human loss has been reported except for the Stock, Material and Capital loss. All the Stock, Material and Capital Assets have been adequately insured. The Company has also taken the Loss of Profit policy on this plant".

Sharon Bio-Medicine Limited has informed the Exchange regarding European Directorate for the Quality of Medicine & Healthcare (EDOM) approval for Plant Located at Plot No. L-6, MIDC, Taloja.

Sharon Bio-Medicine Limited has informed the Exchange that Sharon has completed expansion in its 3 manufacturing facilities. The total investment in expansion has been incurred to the tune nearly Rs. 125 Crores. In Dehradun Formulation plant, the expanded expenditure has been app. Rs 85/- Crores whereas capacity ofthe plant has been increased more than double. Similarly, other plants' capacity has been added between 30% to 50%. The commercial production in Sharon two expanded plants at Taloja near Navi Mumbai have already been started and Dehradun Formulation expanded facility will start produ

Sharon Bio-Medicine Limited has informed the Exchange vide letter dated December 17, 2013 regarding "U.K. Medicines & Health Care Product Regulatory Agency (MHRA) approval (GMP Certificate) of our Dehradun Formulation Plant".

Sharon Bio-Medicine Limited has informed the Exchange vide its letter dated July 22, 2013 regarding "Setting up of Genotoxicity Laboratory at Taloja near Navi Mumbai".

Sharon Bio-Medicine Limited has informed the Exchange vide its letter dated June 11, 2013 regarding "SA- FORD - GLP Toxicology approval in ARGENTINA".

Sharon Bio-Medicine Limited had informed the Exchange regarding approval from Bondholders for rollover of FCCB USD 16.50 Mn for another 5 years. The Company has now informed the Exchange that the said announcement should be read as follows:"The FCCB of USD 16.5 Million which had matured on December 04, 2012, which was further extended by bondholders till February 28, 2013, the bondholders have approved the restructuring proposal which involves extension of tenor of the existing Bonds for 5 years and issue of additional Bonds in lieu of the accrued interest till date. Accordingly, the Company h

Sharon Bio-Medicine Limited has informed the Exchange that the FCCB of USD 16.5 Million which had matured on December 04, 2012, which was further extended by bondholders till February 28, 2013 has been rolled over with the consent of bondholders for another 5 years. Accordingly, the Company have applied to Reserve Bank of India (RBI) as per the guidelines of ECB for their consent.

Sharon Bio-Medicine Limited has informed the Exchange regarding "Extension date of FCCB"

Sharon Bio-Medicine Limited has informed the Exchange vide its letter dated April 03, 2012, regarding "Subsidy/Financial Assistance of Rs. 690 Lacs from Development of Scientific and Industrial Research, Ministry of Science & Technology, New Delhi".

Sharon Bio-Medicine Limited has informed the Exchange that Sharon Bio-Medicine Limited has filed its ANDA for Memantine Hydrochloride Tablets, 5mg and 10mg tablets form its drug product manufacturing facility at Silaqui, Dehradoon, Uttarakhand.